After-Hours Stock Movers 08/23: (CARA) (PANW) (BXC) Higher; (TBPH) (MARK) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Palo Alto Networks (PANW) PT Raised to $500 at Piper Sandler
August 24, 2021 8:48 AM EDTPiper Sandler analyst Rob Owens raised the price target on Palo Alto Networks (NYSE: PANW) to $500.00 (from $450.00) while maintaining an Overweight rating following results.
The analyst commented, "Highlights include billings and revenue acceleration, the first quarter ever of $2B+ bookings, and impressive... More
Palo Alto Networks (PANW) PT Raised to $509 at BTIG
August 24, 2021 7:21 AM EDTBTIG analyst Gray Powerll raised the price target on Palo Alto Networks (NYSE: PANW) to $509.00 (from $460.00) while maintaining a Buy rating.
... MorePalo Alto Networks (PANW) PT Raised to $475 at Cowen
August 24, 2021 6:51 AM EDTCowen analyst Shaul Eyal raised the price target on Palo Alto Networks (NYSE: PANW) to $475.00 (from $425.00) while maintaining an Outperform rating.
The analyst commented, "PANW's better than expected results and improved guidance should alleviate recent investors' concerns about potential margin erosion, mgnt shuffle, and... More
Theravance Biopharma (TBPH) PT Lowered to $18 at Needham & Company
August 24, 2021 6:24 AM EDTNeedham & Company analyst Joseph Stringer lowered the price target on Theravance Biopharma (NASDAQ: TBPH) to $18.00 (from $32.00) while maintaining a Buy rating.
The analyst commented, "TBPH announced yesterday the izencitinib Ph2b RHEA trial in Ulcerative Colitis (UC) failed to demonstrate efficacy vs... More
